secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001193125-25-004435
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics promotes Seth Harmon to CFO effective Jan 1, 2025
-----------------------------------------------------------------------

- Seth Harmon, previously SVP of Finance and Accounting and Principal Financial Officer, appointed CFO effective Jan 1, 2025.
- New base salary of $480,000 and target bonus of 40% of base salary.
- Received equity awards: stock option with grant date value of $1,662,000 and RSUs with grant date value of $554,000.
- Harmon's prior roles include CFO of BioNTech US subsidiary and VP of Finance at Neon Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525004435/0001193125-25-004435-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525004435/d842633d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004435

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer